CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
Top Page
CANbridge Pharmaceuticals Inc.
(1228)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$2.50
▼(-0.79% Downside)
Action:DowngradedDate:01/27/26
The score is primarily held back by weak financial performance (losses, negative equity, and negative cash flows). Technicals are comparatively strong with bullish trend/momentum, but valuation support is limited given the negative P/E and lack of dividend yield data.
Positive Factors
Focus on rare diseases and oncology
Targeting rare diseases and oncology is a durable strategic position: these areas have persistent unmet medical need, regulatory incentives, and potential for premium pricing. Success in these niches can create long-term, high-value revenue streams and durable market exclusivity.
Negative Factors
Negative equity and high leverage
Negative equity and high leverage are structural weaknesses: they limit borrowing capacity, raise refinancing risk, and constrain strategic flexibility. Long-term recovery requires substantial earnings improvement or capital raises, both of which can be difficult in volatile markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Focus on rare diseases and oncology
Targeting rare diseases and oncology is a durable strategic position: these areas have persistent unmet medical need, regulatory incentives, and potential for premium pricing. Success in these niches can create long-term, high-value revenue streams and durable market exclusivity.
Read all positive factors
CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.41B
Dividend YieldN/A
Average Volume (3M)5.03M
Price to Earnings (P/E)0.9
Beta (1Y)1.22
Revenue Growth-40.24%
EPS Growth66.43%
CountryHK
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.12
Shares Outstanding511,252,230
10 Day Avg. Volume2,153,700
30 Day Avg. Volume5,027,972
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)0.62
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model
Company Description
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy...
How the Company Makes Money
CANbridge Pharmaceuticals generates revenue through multiple channels, primarily by developing and commercializing its proprietary drug candidates, which are in various stages of clinical trials. The company may earn income from product sales once...
CANbridge Pharmaceuticals Inc. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.56M | 85.10M | 102.87M | 78.97M | 31.16M | 12.03M |
| Gross Profit | 40.29M | 54.30M | 64.16M | 48.89M | 18.78M | 6.88M |
| EBITDA | -150.16M | -328.69M | -341.43M | -454.63M | -1.06B | -824.41M |
| Net Income | -136.11M | -442.62M | -378.84M | -483.48M | -1.08B | -846.04M |
Balance Sheet | ||||||
| Total Assets | 105.50M | 116.81M | 395.36M | 702.04M | 892.52M | 586.36M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 10.50M | 137.49M | 451.16M | 745.82M | 360.80M |
| Total Debt | 34.97M | 135.78M | 141.93M | 155.28M | 52.10M | 46.90M |
| Total Liabilities | 514.58M | 591.30M | 435.15M | 393.49M | 199.13M | 2.33B |
| Stockholders Equity | -409.08M | -474.49M | -39.79M | 308.56M | 693.39M | -1.75B |
Cash Flow | ||||||
| Free Cash Flow | -14.19M | -122.50M | -319.09M | -315.76M | -592.40M | -305.13M |
| Operating Cash Flow | -14.10M | -122.39M | -278.23M | -280.98M | -587.07M | -151.65M |
| Investing Cash Flow | -38.00K | 13.93M | -26.86M | -34.79M | 126.09M | -153.48M |
| Financing Cash Flow | 0.00 | -18.57M | -28.02M | -20.70M | 854.31M | 679.26M |
CANbridge Pharmaceuticals Inc. Technical Analysis
Positive
2.52
Price Trends
2.70
Positive
2.41
Positive
2.04
Positive
Market Momentum
<0.01
Negative
55.43
Neutral
76.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Positive. The current price of 2.52 is below the 20-day moving average (MA) of 2.61, below the 50-day MA of 2.70, and above the 200-day MA of 2.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.43 is Neutral, neither overbought nor oversold. The STOCH value of 76.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1228.
CANbridge Pharmaceuticals Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$3.70B | -13.26 | 11.40% | ― | 79.98% | -3.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.41B | 0.95 | 8.92% | ― | -40.24% | 66.43% | |
48 Neutral | HK$1.30B | -1.67 | -70.71% | ― | ― | 81.67% | |
44 Neutral | HK$717.58M | -2.18 | 191.92% | ― | ― | 83.89% | |
43 Neutral | HK$1.25B | -2.47 | -27.44% | ― | -57.84% | 24.58% | |
41 Neutral | HK$912.08M | -1.73 | -75.15% | ― | 2.45% | 2.58% |
* Healthcare Sector Average
HK:1228
CANbridge Pharmaceuticals Inc.
2.75
2.61
1864.29%
HK:9939
Kintor Pharmaceutical Ltd
2.64
1.53
137.84%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.19
0.80
57.55%
HK:2197
Clover Biopharmaceuticals Ltd.
2.85
2.65
1325.00%
HK:2257
Sirnaomics Ltd.
6.54
3.49
114.43%
HK:6628
Transcenta Holding Limited
2.82
1.68
147.37%
CANbridge Pharmaceuticals Inc. Corporate Events
CANbridge Grants Share Options and RSUs Equal to 1.25% of Share Capital
Jan 12, 2026
CANbridge Pharmaceuticals has granted 6,372,575 share options to 30 grantees and an equal number of restricted share units (RSUs) to 28 grantees under its post-IPO incentive schemes, representing about 1.25% of its issued share capital. The share ...
CANbridge’s CAN 103 Gains Inclusion in China’s Innovative Drug List
Dec 8, 2025
CANbridge Pharmaceuticals Inc. announced that its enzyme replacement therapy, CAN 103, has been included in China’s first ‘Commercial Health Insurance Innovative Drug List,’ effective January 1, 2026. This inclusion marks a signi...
CANbridge Pharmaceuticals Secures Shareholder Approval for Key Resolutions at EGM
Dec 4, 2025
CANbridge Pharmaceuticals Inc. announced that all resolutions proposed at their Extraordinary General Meeting (EGM) held on December 4, 2025, were passed by shareholders. The resolutions included granting a new general mandate to the company’...
CANbridge Pharmaceuticals to Hold Virtual EGM for Share Issuance Mandate
Nov 19, 2025
CANbridge Pharmaceuticals Inc. announced an extraordinary general meeting (EGM) to be held virtually on December 4, 2025. The meeting will address resolutions including the revocation of the existing general mandate for issuing shares and the appr...
CANbridge Pharmaceuticals Announces EGM and Register Closure
Nov 17, 2025
CANbridge Pharmaceuticals Inc. announced the closure of its register of members in preparation for an extraordinary general meeting (EGM) scheduled for December 4, 2025. This meeting is significant for shareholders as it determines their eligibili...
CANbridge Pharmaceuticals Proposes New General Mandate for Share Issuance
Nov 17, 2025
CANbridge Pharmaceuticals Inc. has announced a proposal to refresh its Existing General Mandate, allowing directors to issue new shares up to 20% of the company’s issued share capital. This move comes after the full utilization of the existi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.